683 Capital Management, LLC Atara Biotherapeutics, Inc. Transaction History

683 Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $282,000 - $462,000	200,000 Added 20.0%	1,200,000 $1.78 Million
Q2 2023 Aug 14, 2023	BUY	$1.5 - $3.04 $1.5 Million - $3.04 Million	1,000,000 New	1,000,000 $1.61 Million
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $2.12 Million - $6.5 Million	-745,000 Reduced 36.43%	1,300,000 $4.91 Million
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $1.01 Million - $2.12 Million	215,000 Added 11.75%	2,045,000 $15.9 Million
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $411,585 - $823,657	48,766 Added 2.74%	1,830,000 $17 Million

Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $13.2 Million - $19.8 Million	1,103,551 Added 162.84%	1,781,234 $31.9 Million
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $5.89 Million - $7.57 Million	456,835 Added 206.85%	677,683 $10.5 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $1.66 Million - $3.3 Million	220,848 New	220,848 $3.22 Million
Q1 2020 May 15, 2020	SELL	$5.69 - $17.78 $142,250 - $444,500	-25,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $272,250 - $419,750	25,000 New	25,000 $412,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.